CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-05 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | −200 | $18.05 | $4K | 16,509 |
| 2022-12-05 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −200 | 105,497 | ||
| 2022-12-02 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise | +2,910 | $2.10 | $6K | 19,419 |
| 2022-12-02 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | −2,910 | $18.20 | $53K | 16,509 |
| 2022-12-02 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −2,910 | 105,697 | ||
| 2022-11-28 | Doshi Dipal President and CEO | Sale | −2,000 | $13.91 | $28K | 182,835 |
| 2022-11-16 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise | +200 | $2.10 | $420 | 16,709 |
| 2022-11-16 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | −200 | $18.10 | $4K | 16,509 |
| 2022-11-16 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −200 | 108,607 | ||
| 2022-10-31 | Dowden Nathan J Chief Operating Officer | Sale | −2,100 | $24.05 | $50K | 45,283 |
| 2022-10-27 | Doshi Dipal President and CEO | Sale | −2,000 | $21.66 | $43K | 184,835 |
| 2022-10-26 | KREHER NERISSA Chief Medical Officer | Option exercise | +4,960 | $2.10 | $10K | 25,676 |
| 2022-10-26 | KREHER NERISSA Chief Medical Officer | Sale | −643 | $21.21 | $14K | 25,033 |
| 2022-10-26 | KREHER NERISSA Chief Medical Officer | Sale | −4,317 | $22.01 | $95K | 20,716 |
| 2022-10-26 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −4,960 | 114,722 | ||
| 2022-10-25 | KREHER NERISSA Chief Medical Officer | Option exercise | +8,040 | $2.10 | $17K | 28,756 |
| 2022-10-25 | KREHER NERISSA Chief Medical Officer | Sale | −4,942 | $20.53 | $101K | 23,814 |
| 2022-10-25 | KREHER NERISSA Chief Medical Officer | Sale | −2,998 | $21.42 | $64K | 20,816 |
| 2022-10-25 | KREHER NERISSA Chief Medical Officer | Sale | −100 | $22.13 | $2K | 20,716 |
| 2022-10-25 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −8,040 | 119,682 |
Page 19 of 26 · 517 trades